Blood Tests for Lung Cancer: Liquid Biopsy, Tumor Markers, Limitations

"Can I just get a blood test for lung cancer?" is one of the most common questions we get. The appeal is obvious: a tube of blood is cheap, painless, and doesn't involve radiation or a 30-second breath-hold inside a scanner. The honest answer is that blood-based testing for lung cancer has improved dramatically in the past five years — but it still doesn't replace a low-dose CT for screening, and the marketing around some commercial tests is well ahead of the evidence. This guide walks through what tumor markers, liquid biopsy, and multi-cancer detection panels can and can't do, with real accuracy numbers and real prices.

Can a Blood Test Find Lung Cancer?

The short answer: sometimes, but not reliably enough to skip imaging. There is no single blood test for lung cancer that the US Preventive Services Task Force, NHS, NCCN, or any major guideline body recommends as a stand-alone screening tool. Low-dose CT (LDCT) of the chest remains the only screening method proven in randomized trials to lower lung cancer mortality.

That said, blood-based testing now plays several legitimate roles around a lung cancer diagnosis: ruling tumors in or out when a CT finds something suspicious, monitoring patients already on treatment, watching for recurrence after surgery, and — in the experimental multi-cancer detection (MCED) space — flagging cancers that conventional screening misses.

If you're searching for "lung cancer in blood test" because you're afraid of CT radiation or just want a one-shot answer, read this guide to the end. The technology is real, but the limits are real too.

Tumor Markers: CEA, CYFRA 21-1, NSE, ProGRP

The oldest category of lung cancer blood markers is serum tumor markers — proteins that lung tumors (and sometimes other tissues) shed into the bloodstream. The standard lung cancer blood markers panel in most Chinese 3A hospitals includes four:

• CEA (Carcinoembryonic Antigen). Elevated in roughly 50-70% of lung adenocarcinoma cases. Also elevated in colon, breast, pancreas, and stomach cancers — so it is not lung-specific.
• CYFRA 21-1 (Cytokeratin Fragment 21-1). The most sensitive marker for non-small-cell lung cancer (NSCLC), especially squamous cell carcinoma. Sensitivity around 50-60% in NSCLC.
• NSE (Neuron-Specific Enolase). Elevated in roughly 70-80% of small-cell lung cancer (SCLC) cases. Useful for distinguishing SCLC from NSCLC.
• ProGRP (Pro-Gastrin-Releasing Peptide). Highly specific for small-cell lung cancer. Sensitivity 60-80% for SCLC, much lower for NSCLC.

The problem: each of these markers individually is only 50-70% sensitive and 80-90% specific. In a screening context — where most people don't have cancer — that produces a flood of false positives and missed early cancers. A 2019 Chinese meta-analysis combining all four markers reported sensitivity around 75% and specificity around 85% for diagnosing lung cancer in symptomatic patients. That sounds reasonable until you compute the positive predictive value in a general screening population: with a 1% prevalence, even an 85%-specific test gives more false alarms than true positives.

Where tumor markers do earn their keep is treatment monitoring. If a patient has a confirmed lung cancer with elevated CEA at baseline, watching CEA fall during chemotherapy and rise again at recurrence is a cheap, repeatable signal that complements imaging.

Liquid Biopsy (ctDNA, Circulating Tumor Cells)

"Liquid biopsy" is a marketing umbrella for a family of newer blood tests that look directly at tumor DNA or tumor cells in the bloodstream. The two main flavors:

• Circulating tumor DNA (ctDNA). Tiny fragments of DNA shed by tumor cells, identifiable by characteristic mutations (EGFR L858R, KRAS G12C, ALK fusions, etc.). Detected by next-generation sequencing of plasma.
• Circulating tumor cells (CTCs). Whole tumor cells captured from blood using antibody-based filtration. Less commonly used clinically — mostly research.

For already-diagnosed lung cancer, liquid biopsy lung cancer testing is now standard of care in several scenarios:

1. Initial molecular profiling when a tissue biopsy is inadequate or risky (e.g., a frail patient with a small peripheral lesion). FDA-approved platforms like Guardant360 and FoundationOne Liquid CDx detect the targetable mutations that determine whether a patient gets a TKI like osimertinib or an immunotherapy.
2. Resistance monitoring. When an EGFR-mutated patient progresses on osimertinib, a liquid biopsy can flag the T790M or C797S resistance mutation that points to the next-line therapy.
3. Minimal residual disease (MRD) monitoring after curative-intent surgery or chemoradiation. Tests like Signatera and ArcherDX can detect ctDNA months before imaging shows recurrence — though "earlier detection" hasn't yet been proven to change survival.

For screening — finding cancer in a healthy person — ctDNA sensitivity for early-stage (Stage I) lung cancer is still poor, around 30-50%. Stage IV cancers shed enough DNA to be detected reliably; Stage I tumors often don't shed enough to be distinguishable from background noise. This is the central limitation of every "blood test for lung cancer" pitched at healthy adults: the cancers worth catching early are the ones the test misses.

Multi-Cancer Detection Tests (Galleri, OneTest)

The most-hyped category of new tests is multi-cancer early detection (MCED) — blood tests that screen for dozens of cancers at once by looking at ctDNA methylation patterns rather than specific mutations.

• Galleri (GRAIL). US-only, $949 cash price, not insurance-covered. Reports a "Cancer Signal Detected" or "No Cancer Signal Detected" result, and when positive, predicts the tissue of origin. Lung cancer is one of the 50+ cancers it claims to detect. Overall sensitivity in the PATHFINDER and SYMPLIFY studies is ~52% across all cancer types and stages, with specificity above 99%. For lung cancer specifically, Stage I sensitivity is around 22%, Stage IV is around 95%. NHS is running the multi-year NHS-Galleri trial in 140,000 adults to see if it changes mortality. Results expected 2026-2027.
• OneTest (20/20 GeneSystems). A protein-marker panel marketed primarily in Asia. Reports per-cancer probabilities and recommends follow-up imaging when positive. Less third-party validation than Galleri but cheaper (around $200-300 in the US, $80-100 in Hong Kong).
• CancerSEEK / DELFI (research-stage). Academic platforms that combine ctDNA, protein markers, and fragmentomics. Not yet commercially available.

Two honest things about MCED testing for lung cancer specifically: (1) Per-cancer Stage I sensitivity is poor — most early lung cancers will be missed. (2) A "Cancer Signal Detected" result means a full workup of CT, PET, endoscopies, and sometimes biopsies even if the signal turns out to be a false alarm or a different cancer entirely. Patients should understand that a positive MCED result is the start of an expensive cascade, not an answer.

Why Blood Tests Don't Replace LDCT for Screening

The bottom-line reason no guideline body recommends a blood test for lung cancer as primary screening: low-dose CT works, and blood tests don't (yet) work as well.

The National Lung Screening Trial (NLST) showed LDCT cut lung cancer mortality by 20% versus chest X-ray in high-risk smokers. The Dutch NELSON trial confirmed roughly 24% mortality reduction in men and 33% in women using a similar LDCT protocol. The trials needed to make a comparable claim for any blood-based test simply haven't reported yet. NHS-Galleri (results 2026-2027) is the closest, and even that is testing a multi-cancer signal, not a lung-specific signal.

LDCT also has a clear actionable output: a measurable nodule with a size, a location, and a Lung-RADS category. A blood test can't tell a surgeon where to look. Even if a future liquid biopsy lung cancer test reaches 80% sensitivity for Stage I disease, you still need imaging to localize the tumor before treatment.

That's the honest tradeoff. Today, a blood test for lung cancer is an adjunct, not a substitute, for LDCT in screening.

When Blood Tests Help (Treatment Monitoring, Recurrence)

Blood-based testing has well-established roles after a lung cancer diagnosis or in specific high-risk surveillance situations:

• Molecular profiling at diagnosis. Especially when tissue is insufficient or rebiopsy is risky, liquid biopsy ctDNA can identify the driver mutation that selects targeted therapy. This is now reimbursed by Medicare and most private US insurers for advanced NSCLC.
• Treatment response monitoring. Falling CEA, CYFRA 21-1, or ctDNA allele frequencies during chemotherapy or TKI therapy correlate with imaging response. Useful between scheduled scans.
• Resistance detection. When a targeted therapy stops working, ctDNA can identify the resistance mutation faster than waiting for a tissue rebiopsy.
• Post-surgical recurrence surveillance. MRD assays (Signatera-style) flag returning cancer months before CT does. Not yet proven to improve survival, but increasingly used at major US and European cancer centers.
• Suspicious nodule risk stratification. A few platforms (Nodify XL2, REVEAL Lung Nodule) combine blood biomarkers with clinical features to refine the probability that an indeterminate CT nodule is malignant — helping decide between watch-and-wait and biopsy.

None of these are the same as "I want a blood test instead of a CT scan." If that's what you're after, the answer is: not yet.

Accuracy: Sensitivity vs Specificity

When evaluating any blood test for lung cancer, two numbers matter:

• Sensitivity = of people who do have lung cancer, what fraction does the test catch? Low sensitivity means missed cancers (false negatives).
• Specificity = of people who don't have lung cancer, what fraction does the test correctly clear? Low specificity means false alarms (unnecessary CTs, biopsies, anxiety).

A test with 95% sensitivity and 95% specificity sounds great. But in a population where 1% have undiagnosed lung cancer (roughly the rate in heavy smokers eligible for LDCT), here's what happens when you screen 10,000 people:

• True positives caught: 95 of the 100 actual cancers.
• False positives flagged: 495 of the 9,900 healthy people get a positive result.

Even at 95% specificity, more than 80% of positive results are false alarms. This is why specificity matters even more than sensitivity in screening — and why Galleri's 99%+ specificity is more impressive than its 52% sensitivity sounds.

LDCT, for comparison, runs roughly 95% sensitivity for Stage I lung cancer and 75-80% specificity. The lower specificity is balanced by the fact that "positive" means a measurable nodule that can be followed up with serial imaging rather than immediate biopsy.

The takeaway: when a vendor advertises a sensitivity number for their lung cancer blood markers test, ask what stage it was measured at, what population was tested, and what the specificity was. A 90% sensitivity for Stage IV is not the same product as a 30% sensitivity for Stage I.

Lung Cancer Blood Panels at China 3A Hospitals: ~$80

For patients researching options in China, here is what a lung cancer blood panel actually costs and includes at typical Class 3A (tertiary) hospitals:

Standard lung tumor marker panel (CEA + CYFRA 21-1 + NSE + ProGRP): RMB 500-650 ($70-90). Same-day blood draw, results in 24-48 hours. Available at virtually every 3A hospital in Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, and Chengdu.

Extended cancer panel (lung + GI + liver markers, ~10 markers): RMB 800-1,200 ($110-170). Useful as a broader baseline if you're already doing a comprehensive health check.

Liquid biopsy (ctDNA NGS panel, 50-100 genes): RMB 6,000-12,000 ($850-1,700). Mostly used for diagnosed cancer patients selecting targeted therapy. Not a screening test.

Combined with LDCT in a screening package: RMB 1,200-1,800 ($170-250) for LDCT + tumor markers + radiologist report. This is the most common configuration we book through SinoCareLink for international patients who want both a structural answer (LDCT) and a baseline biomarker number (CEA, CYFRA) to monitor over years.

For context, the same lung cancer blood markers panel runs $300-500 cash in the US (LabCorp, Quest) and £200-300 at UK private labs. Liquid biopsy panels run $2,500-5,000 in the US, $1,500-3,000 in the UK.

If you are coming to China for a health checkup, adding a lung tumor marker panel to your LDCT is typically a small marginal cost ($80) and gives you a baseline if anything comes up later. Treat the marker numbers as one data point, not a verdict.

Frequently Asked Questions

Can a blood test alone diagnose lung cancer?
No. Even when tumor markers or ctDNA are positive, diagnosis requires tissue confirmation — either a needle biopsy of a lung lesion or a bronchoscopic biopsy. Blood tests can raise suspicion, monitor treatment, or detect resistance mutations, but no oncologist will start chemotherapy or radiation based on a blood test alone.

Are tumor markers like CEA accurate for screening healthy people?
Not accurate enough for stand-alone screening. CEA has a sensitivity of 50-70% for lung adenocarcinoma and is also elevated in other cancers, smoking, inflammation, and benign liver disease. Used alone in healthy populations, it produces too many false alarms and misses too many early cancers. It's most useful as a baseline number in patients already diagnosed.

What about the Galleri test — does it work for lung cancer?
Galleri detects a multi-cancer signal and predicts tissue of origin. For lung cancer, its overall sensitivity is around 52% across all stages but only ~22% for Stage I disease. Specificity is 99%+. The NHS-Galleri trial (140,000 participants) is testing whether this reduces cancer mortality; results are expected 2026-2027. Until then, it's not a substitute for LDCT in eligible high-risk adults.

If my LDCT is normal, do I also need a blood test for lung cancer?
Generally no, for screening purposes. If LDCT is clean and you have no symptoms, adding tumor markers rarely changes management. Where blood markers do add value is as a baseline — if you ever develop symptoms or a future nodule, having a prior CEA or CYFRA value helps interpret the new one. In a comprehensive health check it's often worth the $80.

Can liquid biopsy detect lung cancer before symptoms appear?
Sometimes for advanced cancers, rarely for early-stage. ctDNA detection sensitivity scales with tumor burden — Stage IV cancers shed plenty, Stage I cancers often shed less than the assay's detection floor. This is why no major guideline body recommends liquid biopsy for primary screening yet.

Is a blood test enough if I'm afraid of CT radiation?
LDCT delivers about 1-2 mSv per scan — comparable to 6 months of natural background radiation, and far less than a regular chest CT (around 7 mSv). For someone meeting USPSTF or NELSON screening criteria, the cancer-detection benefit of annual LDCT outweighs the radiation risk. A blood test, even Galleri, is not yet an evidence-based substitute. If you are not in a high-risk group, the right question may be whether you need screening at all rather than which modality to use.

Why do tumor marker panels in China include four markers instead of one?
Each marker has different sensitivity for different lung cancer subtypes — CYFRA 21-1 for squamous NSCLC, CEA for adenocarcinoma, NSE and ProGRP for small-cell. Combining four catches more subtypes than any one alone, at small added cost. A combined panel reaches roughly 75% sensitivity in symptomatic patients, versus 50-60% for any single marker.

How often should I repeat lung cancer blood markers?
For healthy adults using markers as a baseline, every 1-2 years alongside other annual labs is reasonable. For patients diagnosed with lung cancer, monitoring frequency follows oncologist guidance — typically every 3 months during active treatment, every 6-12 months during long-term surveillance.

---

A blood test for lung cancer is a real and useful tool — for treatment monitoring, recurrence surveillance, and matching patients to targeted therapies. It is not, today, a substitute for low-dose CT in screening, and you should be cautious about marketing that suggests otherwise. SinoCareLink coordinates LDCT scans, lung tumor marker panels, and full diagnostic workups at vetted Class 3A hospitals across mainland China — typically at one-fifth to one-tenth of US or UK private prices — with English-language reports and a single point of contact.

Contact us for a coordinated quote →